Nakayama Tomohiko, Umehara Hidehiro, Mawatari Kazuaki, Tomioka Yukiko, Yoshida Tomohiro, Matsuda Hiroya, Matsumoto Yui, Masuda Rumiko, Kamishikiryo Toshiharu, Fuchikami Manabu, Nakataki Masahito, Takahashi Akira, Tajima Atsushi, Okada Go, Numata Shusuke
Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Department of Preventive Environment and Nutrition, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Neuropsychiatr Dis Treat. 2025 May 18;21:1067-1073. doi: 10.2147/NDT.S508021. eCollection 2025.
Bipolar disorder (BD) is a psychiatric disorder characterized by recurrent episodes of mania and depression. However, the pathophysiology has not yet been fully elucidated.
In this study, we employed capillary electrophoresis time-of-flight mass spectrometry to measure 34 plasma metabolites and compared the levels between individuals with BD (N = 64, male/female = 30/34, age [mean ± S.D.] = 51.4 ± 12.0 years) and non-psychiatric controls (N = 92, male/female = 32/60, age = 38.6 ± 13.4 years).
Significant differences in 12 plasma metabolites, including kynurenine and tryptophan, were observed between the two groups (q < 0.05).
These findings support the involvement of amino acid dysregulation in the pathophysiology of BD. However, the cross-sectional design, lack of control for medication, diet, and smoking, and the use of peripheral rather than central samples limit the generalizability of the results. Further longitudinal and mechanistic studies are needed. Integration with clinical, imaging, and genetic data in future research may facilitate the development of metabolomics-based biomarkers.
双相情感障碍（BD）是一种以躁狂和抑郁反复发作发为特征的精神障碍。然而，其病理生理学尚未完全阐明。
在本研究中，我们采用毛细管电泳飞行时间质谱法测量了34种血浆代谢物，并比较了双相情感障碍患者（N = 64，男/女 = 30/34，年龄[均值±标准差]= 51.4±12.0岁）和非精神科对照者（N = 92，男/女 = 32/60，年龄 = 38.6±13.4岁）之间的水平。
两组之间观察到12种血浆代谢物存在显著差异，包括犬尿氨酸和色氨酸（q < 0.05）。
这些发现支持氨基酸失调参与双相情感障碍的病理生理学过程。然而，横断面设计、缺乏对药物治疗、饮食和吸烟的控制，以及使用外周而非中枢样本限制了结果的普遍性。需要进一步的纵向和机制研究。未来研究中将临床、影像学和基因数据整合起来可能会促进基于代谢组学的生物标志物的开发。
